actin related protein T3Genealiases: ARP-T3 · ARPM1
Q-omics provides the consensus-scored ACTRT3 profile across patient tissues and cancer cell-line models. ACTRT3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ACTRT3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ACTRT3 RNA expression shows 17,744 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, HNSC, and THYM as cancer lineages where ACTRT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTRT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTRT3 survival associations across molecular data types. ACTRT3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTRT3 RNA expression–survival associations across cancer types. High ACTRT3 expression shows unfavorable associations in LUAD, UCEC, ACC and ESCA, but favorable associations in KICH and UVM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for ACTRT3 RNA expression.
This table summarizes ACTRT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACTRT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTRT3 shows lower tumor expression in KICH, KIRC, THCA and KIRP and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher ACTRT3 RNA expression in tumor versus normal tissue (log2 FC = +1.333, t-test p < 0.001).
This table shows molecular features associated with ACTRT3 in patient tissues and cancer cell lines. In patient samples, ACTRT3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTRT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
